Odyssey Therapeutics presented a $433 million cash balance as of June 30, with expected funding for operations into H2 2028. For investors, the stated runway frames the company’s development plans, including an October 2026 update for OD-001 and a H2 2026 CTA filing for OD-002.

Key Highlights

  • The company reports $433 million in cash as of June 30, 2026, with expected operations funding into H2 2028.
  • OD-001 is expected to generate updated monotherapy data in October 2026 at UEG.
  • OD-002 has a CTA filing anticipated in H2 2026, followed by Phase 1/2 initiation in H1 2027.

Odyssey Therapeutics, Inc. (NASDAQ: ODTX) outlined a $433 million cash balance as of June 30 and said it expects the funds to support operations into H2 2028. The presentation also set out clinical milestones for its inflammatory and autoimmune disease programs.

$433 Million Cash Balance and Clinical Milestones

The September 2026 presentation identifies OD-001 as a small-molecule program for ulcerative colitis and Crohn’s disease. Updated monotherapy data are expected in October 2026 at UEG, followed by a H2 2027 Phase 2a combination readout and a H2 2027 Phase 2b monotherapy readout. OD-002, another small-molecule program, targets cutaneous lupus erythematosus, nephropathies and B cell-mediated diseases, with a CTA filing planned for H2 2026 and Phase 1/2 initiation in H1 2027. Odyssey also lists OD-003, a protein program for atopic dermatitis, systemic lupus erythematosus and alopecia areata, and OD-004, a protein program for chronic obstructive pulmonary disease and asthma. The company says its Balance Sheet is expected to fund operations into H2 2028.

Inflammatory Bowel Disease Market Information

Odyssey identifies inflammatory bowel disease as a $100B current market. It also lists a $30B current market and $65B future market, and a $25B current market and $40B future market, for other disease areas.